Structure-Modifying Capacity of Anti-Tumour Necrosis Factor- Therapy in Ankylosing Spondylitis

Author： Filip De Keyser   Baeten Dominique   Filip Van den Bosch   Kruithof Elli   Verbruggen Gust   Mielants Herman   Veys Eric  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.64, Iss.24, 2004-01, pp. : 2793-2811

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-tumour necrosis factor therapy in seronegative spondyloarthritis

By Swales Catherine   Bowness Paul  

Clinical Medicine, Vol. 5, Iss. 3, 2005-05 ,pp. : 219-222

Royal College Of Physicians

Access to resources Recommend Favorite

Anti-Tumour Necrosis Factor Therapy for Ulcerative Colitis: Evidence to Date

By Thukral Chandrashekhar   Cheifetz Adam   Peppercorn Mark A.  

Drugs, Vol. 66, Iss. 16, 2006-01 ,pp. : 2059-2065

Adis International

Access to resources Recommend Favorite

Tumour necrosis factor-α inhibitors have a growing role in managing late-onset ankylosing spondylitis and spondylarthritis

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 2, 2011-02 ,pp. : 13-16

Adis International

Access to resources Recommend Favorite

Anti-Tumour Necrosis Factor-α Therapy for Rheumatoid and Other Inflammatory Arthropathies: Update on Safety in Older Patients

By Ornetti Paul   Chevillotte Hélène   Zerrak Amal   Jean Francis Maillefert  

Drugs & Aging, Vol. 23, Iss. 11, 2006-01 ,pp. : 855-860

Adis International

Access to resources Recommend Favorite

Anti-TNF-α therapy in ankylosing spondylitis

By Wendling Daniel   Toussirot Eric  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 7, 2004-07 ,pp. : 1497-1507

Informa Healthcare

Access to resources Recommend Favorite